1 The median duration between CTCA was 4.3years.
2 The median duration between tests was 7.0 [7.0-8.0] days.
3 The median duration between the first and the current episode
4 The median duration from ICI resumption to IMDC recurrence wa
5 The median duration from IMDC to restart of ICI treatment was
6 The median duration of anti-TB treatment was 50 (IQR, 46-66)
7 The median duration of anti-TB treatment was 50 (IQR:46-66) w
8 A 7-day difference in
the median duration of covering antibiotics was achieved.
9 The median duration of DOAC exposure was 5.3 weeks (IQR 4.0-7
10 The median duration of fecal shedding was 28 days (95% CI, 19
11 had been enrolled in an ongoing long-term extension study;
the median duration of follow-up across both studies was 42 m
12 At the time of the analysis (December 31, 2018),
the median duration of follow-up for mortality was 24 years (
13 The median duration of follow-up was 13.9 months (IQR 9.8-17.
14 In the SOS reference cohort,
the median duration of follow-up was 20 years (interquartile
15 The median duration of follow-up was 22 months (range, 0 to 7
16 At the time of data cutoff (Jan 31, 2020),
the median duration of follow-up was 24.0 months (IQR 21.4-28
17 The median duration of follow-up was 28.6 months.
18 The median duration of follow-up was 35 weeks.
19 The median duration of follow-up was 6.8 years (interquartile
20 The median duration of general anaesthesia was 54 min (IQR 41
21 Interval-censored exponential survival models estimated
the median duration of H. somni and P. multocida carriage at
22 The median duration of hospitalization was 7 days (interquart
23 The median duration of index hospitalization was 6 days (IQR,
24 The median duration of intraocular PFCL retainment was 14 day
25 The median duration of maternal therapy at birth was 55 days
26 The median duration of monitoring was 47 hours (15-88 hr), an
27 The median duration of overall survival in cohort A was 19.1
28 In cohort B,
the median duration of overall survival was 14.1 months with
29 Total follow-up was 38.2 months, during which
the median duration of overall survival was 5.5 months (IQR 2
30 The median duration of persistence in the absence of curative
31 l count was 620/uL (interquartile range, 447-826/ u L), and
the median duration of prior ART use, 9.5 years (5.3-14.8) ye
32 ; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and
the median duration of progression-free survival was 7.8 mont
33 The median duration of response for patients with tFL was 10.
34 The median duration of response was 11.1 months (4.2-not esti
35 The median duration of response was 30.1 months (95% CI, 18.1
36 The median duration of response was 4.1 months with ten (71%)
37 The median duration of response was 4.4 months, median progre
38 was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and
the median duration of response was 7.7 months (95% CI, 4.9 t
39 Among 45 responders,
the median duration of response was 8.0 months (95% CI 6.5-14
40 The median duration of response was 9.1 months (95% CI, 6.4-1
41 The median duration of response was not reached (95% CI 9.0-n
42 The median duration of response was not reached (lower 95% CI
43 The median duration of response was not reached, with a media
44 The median duration of study eye monitoring after IVAN exit w
45 The median duration of study follow-up was 9.3 months (IQR 5.
46 The median duration of symptoms prior to randomization was 5
47 The median duration of the neoadjuvant treatment period was 5
48 The median duration of time between the onset of pancreatitis
49 The median duration of treatment hiatus was 12 months.
50 The median duration of VV ECMO therapy for patients who have